Zeeshan Saeed - FSD Pharma President Director
| HUGEDelisted Stock | USD 0.09 0 4.56% |
President
Mr. Zeeshan Saeed is President, Director of the Company. Mr. Saeed is an entrepreneur was involved with FV Pharma for over four years. Mr. Saeed provided consulting advice to FV Pharma and was instrumental for raising the initial seed capital. He played a key role in bringing together a team of professionals in the development of the companys business plan. He has experience in international capital markets and has helped various startups with the process of raising initial funding and getting listed on various stock exchanges. Mr. Saeed is an Engineer by qualification and is currently the Executive Vice President of FV Pharma. Before entering capital markets Mr. Saeed was the founder and CEO of Platinum Telecommunications Inc since 2018.
| Age | 54 |
| Tenure | 6 years |
| Phone | 416 854 8884 |
| Web | https://www.fsdpharma.com |
FSD Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3374) % which means that it has lost $0.3374 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6403) %, meaning that it created substantial loss on money invested by shareholders. FSD Pharma's management efficiency ratios could be used to measure how well FSD Pharma manages its routine affairs as well as how well it operates its assets and liabilities.FSD Pharma Class currently holds 337.46 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. FSD Pharma Class has a current ratio of 3.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about FSD Pharma's use of debt, we should always consider it together with its cash and equity.
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. FSD Pharma Class (HUGE) is traded on NASDAQ Exchange in USA and employs 10 people. Management Performance
| Return On Equity | -0.64 | |||
| Return On Asset | -0.34 |
FSD Pharma Class Leadership Team
Elected by the shareholders, the FSD Pharma's board of directors comprises two types of representatives: FSD Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FSD. The board's role is to monitor FSD Pharma's management team and ensure that shareholders' interests are well served. FSD Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, FSD Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lakshmi Kotra, Chief Inc | ||
| Kevin Cassidy, Vice QualityLucid | ||
| Donal CPA, Chief Officer | ||
| Zeeshan Saeed, President Director | ||
| Dr BPHARM, CEO Director | ||
| Maryann Adesso, Corporate Secretary | ||
| Nathan CPA, Chief Officer | ||
| Andrzej MD, Vice Lucid | ||
| Anthony Durkacz, Co-Chairman of the Board | ||
| Randell Mack, President BioSciences |
FSD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is FSD Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | 4.57 M | |||
| Shares Outstanding | 46.06 M | |||
| Shares Owned By Insiders | 9.74 % | |||
| Shares Owned By Institutions | 2.81 % | |||
| Number Of Shares Shorted | 176.97 K | |||
| Price To Earning | (1.53) X | |||
| Price To Book | 0.50 X | |||
| Price To Sales | 91.86 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in FSD Stock
If you are still planning to invest in FSD Pharma Class check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the FSD Pharma's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |